BiotechTube

PLD Chemotherapy + CDX-1140 + CDX-301

Phase 1Recruiting
1 views this week 0 watching💤 Quiet
Interest: 30/100
30
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

HER2-negative Breast Cancer

Conditions

HER2-negative Breast Cancer, Metastatic Breast Cancer

Trial Timeline

Apr 20, 2022 → Apr 20, 2026

NCT ID
NCT05029999

About PLD Chemotherapy + CDX-1140 + CDX-301

PLD Chemotherapy + CDX-1140 + CDX-301 is a phase 1 stage product being developed by Celldex Therapeutics for HER2-negative Breast Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05029999. Target conditions include HER2-negative Breast Cancer, Metastatic Breast Cancer.

What happened to similar drugs?

1 of 8 similar drugs in HER2-negative Breast Cancer were approved

Approved (1) Terminated (0) Active (7)
✅Zoledronic acid + Standard TherapyNovartisApproved
🔄E7389 (Eribulin Mesylate) + Vinorelbine injectionEisaiPhase 3
🔄Fluzoparib; Apatinib + Fluzoparib + Physician's choice chemotherapyJiangsu Hengrui MedicinePhase 3
🔄AZD9833 + AZD9833 Placebo + Anastrozole + Anastrozole placebo + Letrozole + Letrozole placebo + Palbociclib + Abemaciclib + Luteinizing hormone-releasing hormone (LHRH) agonist + RibociclibAstraZenecaPhase 3
🔄AZD9833 + Anastrozole + Anastrozole placebo + AZD9833 placebo + Palbociclib + Luteinizing hormone-releasing hormone (LHRH) agonistAstraZenecaPhase 3
🔄Giredestrant + Giredestrant-matched Placebo + Letrozole + Letrozole-matched Placebo + Palbociclib + LHRH AgonistRochePhase 3
🔄Giredestrant + Fulvestrant + Abemaciclib + Palbociclib + Ribociclib + LHRH AgonistRochePhase 3

Hype Score Breakdown

Clinical
6
Activity
15
Company
9
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05029999Phase 1Recruiting

Competing Products

19 competing products in HER2-negative Breast Cancer

See all competitors
ProductCompanyStageHype Score
E7389 (Eribulin Mesylate) + Vinorelbine injectionEisaiPhase 3
40
Durvalumab + EribulinEisaiPhase 1
29
Fluzoparib; Apatinib + Fluzoparib + Physician's choice chemotherapyJiangsu Hengrui MedicinePhase 3
36
AZD9833 + AZD9833 Placebo + Anastrozole + Anastrozole placebo + Letrozole + Letrozole placebo + Palbociclib + Abemaciclib + Luteinizing hormone-releasing hormone (LHRH) agonist + RibociclibAstraZenecaPhase 3
44
AZD9833 + Anastrozole + Anastrozole placebo + AZD9833 placebo + Palbociclib + Luteinizing hormone-releasing hormone (LHRH) agonistAstraZenecaPhase 3
44
[14C]AZD9833 Oral Solution, 75 mgAstraZenecaPhase 1
29
AZD9833 + FulvestrantAstraZenecaPhase 2
39
AZD9833AstraZenecaPhase 2
35
PembrolizumabMerckPhase 2
39
Vinorebine, Everolimus + VinorelbineNovartisPhase 2
35
L-NMMANovartisPhase 2
42
Zoledronic acid + Standard TherapyNovartisApproved
43
LEE011 + Letrozole + Tamoxifen + Fulvestrant + goserelinNovartisPhase 1
29
Giredestrant + Giredestrant-matched Placebo + Letrozole + Letrozole-matched Placebo + Palbociclib + LHRH AgonistRochePhase 3
44
Giredestrant + Fulvestrant or an Aromatase Inhibitor (Physician Choice) + LHRH AgonistRochePhase 2
39
Giredestrant + Fulvestrant + Abemaciclib + Palbociclib + Ribociclib + LHRH AgonistRochePhase 3
47
Capecitabine + Carboplatin + Cisplatin + Sacituzumab govitecanGilead SciencesPhase 3
44
Non-Investigational Antibody-Drug Conjugates (ADC)Gilead SciencesPre-clinical
33
ADG106 + Doxorubicin + Cyclophosphamide + PaclitaxelAdagenePhase 1/2
26